Senate File 2246 - Introduced SENATE FILE 2246 BY BOLKCOM A BILL FOR An Act relating to the regulation of medical cannabidiol 1 under the medical cannabidiol Act, including provisions 2 relating to altering the list of debilitating medical 3 conditions for which the use of medical cannabidiol would be 4 medically beneficial, the form and quantity in which medical 5 cannabidiol may be dispensed, and the definition of medical 6 cannabidiol. 7 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: 8 TLSB 5979XS (5) 87 ss/rh

S.F. 2246 Section 1. Section 124E.2, subsection 2, paragraph b, Code 1 2018, is amended to read as follows: 2 b. Multiple sclerosis with severe and persistent muscle 3 spasms . 4 Sec. 2. Section 124E.2, subsection 2, Code 2018, is amended 5 by adding the following new paragraphs: 6 NEW PARAGRAPH . j. Glaucoma. 7 NEW PARAGRAPH . k. Ehlers-Danlos syndrome. 8 NEW PARAGRAPH . l. Post-traumatic stress disorder. 9 NEW PARAGRAPH . m. Tourette’s syndrome. 10 NEW PARAGRAPH . n. Muscular dystrophy. 11 NEW PARAGRAPH . o. Huntington’s disease. 12 NEW PARAGRAPH . p. Alzheimer’s disease. 13 NEW PARAGRAPH . q. Complex regional pain syndrome, types I 14 and II. 15 NEW PARAGRAPH . r. Rheumatoid arthritis. 16 NEW PARAGRAPH . s. Polyarteritis nodosa. 17 NEW PARAGRAPH . t. Any other chronic or debilitating disease 18 or medical condition or its medical treatment approved by the 19 department pursuant to rule. 20 Sec. 3. Section 124E.2, subsection 6, Code 2018, is amended 21 by striking the subsection and inserting in lieu thereof the 22 following: 23 6. “Medical cannabidiol” means any pharmaceutical grade 24 cannabinoid used for medicinal purposes pursuant to rules of 25 the board, including tetrahydrocannabinols naturally contained 26 in a plant of the genus Cannabis (Cannabis plant) as well 27 as synthetic equivalents of the substances contained in the 28 Cannabis plant, or in the resinous extractives of such plant, 29 and synthetic substances, derivatives, and their isomers with 30 similar chemical structure and pharmacological activity to 31 those substances contained in the plant, such as the following: 32 a. 1 cis or trans tetrahydrocannabinol, and their optical 33 isomers. 34 b. 6 cis or trans tetrahydrocannabinol, and their optical 35 -1- LSB 5979XS (5) 87 ss/rh 1/ 3

S.F. 2246 isomers. 1 c. 3,4 cis or trans tetrahydrocannabinol, and their optical 2 isomers. (Since nomenclature of these substances is not 3 internationally standardized, compounds of these structures, 4 regardless of numerical designation of atomic positions 5 covered.) 6 d. Nabilone [another name for nabilone: (+-) - 7 trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy 8 -6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one]. 9 Sec. 4. Section 124E.5, subsection 4, Code 2018, is amended 10 to read as follows: 11 4. Recommendations made by the medical cannabidiol board 12 pursuant to subsection 3 , paragraphs “b” and “e” , shall be made 13 to the board of medicine department for consideration, and if 14 approved, shall be adopted by the board of medicine department 15 by rule. 16 Sec. 5. Section 124E.11, subsection 2, paragraph c, Code 17 2018, is amended to read as follows: 18 c. Establish the form and quantity of medical cannabidiol 19 allowed to be dispensed to a patient or primary caregiver 20 pursuant to this chapter as appropriate to serve the medical 21 needs of patients with debilitating medical conditions, subject 22 to recommendation by the medical cannabidiol board and approval 23 by the board of medicine . 24 EXPLANATION 25 The inclusion of this explanation does not constitute agreement with 26 the explanation’s substance by the members of the general assembly. 27 This bill relates to the regulation of medical cannabidiol. 28 The bill adds glaucoma, Ehlers-Danlos syndrome, post-traumatic 29 stress disorder, Tourette’s syndrome, muscular dystrophy, 30 Huntington’s disease, Alzheimer’s disease, complex regional 31 pain syndrome types I and II, rheumatoid arthritis, 32 polyarteritis nodosa, and any other chronic or debilitating 33 disease or medical condition or its medical treatment approved 34 by the department of public health pursuant to rule to the 35 -2- LSB 5979XS (5) 87 ss/rh 2/ 3

S.F. 2246 definition of “debilitating medical condition” for which the 1 use of medical cannabidiol would be medically beneficial. The 2 bill also removes the requirement that multiple sclerosis 3 be accompanied by severe and persistent muscle spasms to be 4 considered a debilitating medical condition. 5 The bill alters the definition of medical cannabidiol. 6 The bill requires the medical cannabidiol board to make 7 recommendations regarding the alteration of the list of 8 debilitating medical conditions for which the use of medical 9 cannabidiol would be medically beneficial and the form and 10 quantity in which medical cannabidiol may be dispensed to the 11 department of public health. Current law requires that such 12 recommendations be made to the Iowa board of medicine. 13 -3- LSB 5979XS (5) 87 ss/rh 3/ 3